Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$148.14

(0.00%)

09:16
01/23/18
01/23
09:16
01/23/18
09:16

Johnson & Johnson sees apalutamide approval in 2018

Johnson & Johnson CEO Alex Gorsky said that in 2018 the company expects approval for apalutamide and will file for the approval of esketamine in treatment resistant depression. J&J expects to file for the approval of seven more products by 2021 for a total of 10, each with more than $1B peak revenue potential, as previously stated, Gorsky added.

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

JNJ Johnson & Johnson
$148.14

(0.00%)

01/02/18
JPMS
01/02/18
DOWNGRADE
Target $150
JPMS
Neutral
Johnson & Johnson downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Weinstein downgraded Johnson & Johnson (JNJ) to Neutral with an unchanged price target of $150. The stock closed Friday down 81c to $139.72. The analyst sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. He remains "fundamentally bullish" on the company, however. Weinstein this morning upgraded both Abbott Laboratories (ABT) and Baxter International (BAX) to Overweight.
01/02/18
01/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) downgraded to Neutral from Overweight at JPMorgan with analyst Michael Weinstein saying he sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. 2. PG&E (PCG) downgraded to Sell from Neutral at Guggenheim and to Neutral from Buy at Goldman Sachs. Goldman analyst Michael Lapides saying resolution of claims from the California wildfires, if inverse condemnation is applied, could take years and "cash flow/balance sheet impacts could prove significant still." 3. Allstate (ALL) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying the company's margin expansion story has played out. 4. Cabot Oil & Gas (COG) downgraded two notches to Underperform from Outperform at Raymond James with analyst John Freeman citing valuation after "considerable" 2017 share outperformance. 5. Windstream (WIN) downgraded to Underweight from Neutral at JPMorgan with analyst Philip Cusick saying he sees fundamental business challenges continuing in both the near and long term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/04/18
RBCM
01/04/18
NO CHANGE
Target $54
RBCM
Outperform
Pacira price target raised to $54 from $50 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Pacira (PCRX) to $54 and kept his Outperform rating. Stanicky says his focus is on the company's expected pre-announcement for Q4 this week and his upcoming discussion with CEO Dave Stack on Monday regarding changes from CMS around unbundling of payments that could represent a game changing opportunity for the company's EXPAREL. The analyst notes that traction is building around Pacira's relationship with Johnson & Johnson (JNJ) on the ortho selling side, which marks about half of its revenue.
01/18/18
MSCO
01/18/18
NO CHANGE
Target $157
MSCO
Equal Weight
Zytiga ruling a headwind, but doesn't change J&J thesis, says Morgan Stanley
Morgan Stanley analyst David Lewis noted that Johnson & Johnson suffered an adverse Zytiga IPR ruling, which he calls an incremental headwind. However, he added that a possible earlier generic Zytiga entry is irrelevant to his net present value for J&J shares and doesn't change his view that its Pharma growth accelerates in 2018. Lewis keeps an Equal Weight rating and $157 price target on J&J shares.

TODAY'S FREE FLY STORIES

APOP

Cellect Biotechnology

$2.79

(0.00%)

07:27
01/23/19
01/23
07:27
01/23/19
07:27
Hot Stocks
Cellect Biotechnology reports clinical and regulatory milestone targets »

Cellect Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBPX

Continental Building

$25.55

-0.32 (-1.24%)

07:25
01/23/19
01/23
07:25
01/23/19
07:25
Downgrade
Continental Building rating change  »

Continental Building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

Bluebird Bio

$125.28

-4.68 (-3.60%)

07:25
01/23/19
01/23
07:25
01/23/19
07:25
Recommendations
Bluebird Bio analyst commentary  »

Bluebird Bio price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,634.15

-61.86 (-3.65%)

07:24
01/23/19
01/23
07:24
01/23/19
07:24
Recommendations
Amazon.com analyst commentary  »

Amazon Q4 results should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 28

    Jan

  • 31

    Jan

  • 04

    Feb

  • 20

    Feb

  • 03

    Mar

REPL

Replimune Group

$10.60

0.15 (1.44%)

07:24
01/23/19
01/23
07:24
01/23/19
07:24
Downgrade
Replimune Group rating change  »

Replimune Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBIX

Neurocrine

$91.33

-0.13 (-0.14%)

07:23
01/23/19
01/23
07:23
01/23/19
07:23
Downgrade
Neurocrine rating change  »

Neurocrine downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

WMT

Walmart

$97.47

-0.28 (-0.29%)

07:23
01/23/19
01/23
07:23
01/23/19
07:23
Upgrade
Walmart rating change  »

Morgan Stanley upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

GTX

Garrett Motion

$15.24

-0.56 (-3.54%)

07:22
01/23/19
01/23
07:22
01/23/19
07:22
Upgrade
Garrett Motion rating change  »

Garrett Motion upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LJPC

La Jolla

$6.04

-0.24 (-3.82%)

07:22
01/23/19
01/23
07:22
01/23/19
07:22
Upgrade
La Jolla rating change  »

La Jolla upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTHX

G1 Therapeutics

$19.56

-0.56 (-2.78%)

07:21
01/23/19
01/23
07:21
01/23/19
07:21
Downgrade
G1 Therapeutics rating change  »

G1 Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIDX

Eidos Therapeutics

$12.64

-0.04 (-0.32%)

07:20
01/23/19
01/23
07:20
01/23/19
07:20
Downgrade
Eidos Therapeutics rating change  »

Eidos Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MXCYY

Metso

$0.00

(0.00%)

07:20
01/23/19
01/23
07:20
01/23/19
07:20
Hot Stocks
Metso's Shareholders' Nomination Board to propose Mikael Lilius as chair »

Metso's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOVA

Dova Pharmaceuticals

$7.76

-0.47 (-5.71%)

07:20
01/23/19
01/23
07:20
01/23/19
07:20
Downgrade
Dova Pharmaceuticals rating change  »

Dova Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

  • 30

    Jun

APLS

Apellis

$13.46

-1.42 (-9.54%)

07:19
01/23/19
01/23
07:19
01/23/19
07:19
Downgrade
Apellis rating change  »

Apellis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$298.80

-3.46 (-1.14%)

07:18
01/23/19
01/23
07:18
01/23/19
07:18
Downgrade
Tesla rating change  »

Tesla downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

IP

International Paper

$45.69

0.03 (0.07%)

07:15
01/23/19
01/23
07:15
01/23/19
07:15
Upgrade
International Paper rating change  »

Stephens says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

EHTH

eHealth

$45.38

-0.85 (-1.84%)

07:15
01/23/19
01/23
07:15
01/23/19
07:15
Recommendations
eHealth analyst commentary  »

eHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

07:15
01/23/19
01/23
07:15
01/23/19
07:15
General news
FX Update: The dollar has traded flat-to-softer »

FX Update: The dollar has…

MAS

Masco

$31.00

-1.21 (-3.76%)

07:13
01/23/19
01/23
07:13
01/23/19
07:13
Initiation
Masco initiated  »

Masco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

HII

Huntington Ingalls

$196.46

-3.82 (-1.91%)

07:13
01/23/19
01/23
07:13
01/23/19
07:13
Downgrade
Huntington Ingalls rating change  »

Barclays double…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

CMCSA

Comcast

$35.16

-1.05 (-2.90%)

07:12
01/23/19
01/23
07:12
01/23/19
07:12
Hot Stocks
Breaking Hot Stocks news story on Comcast »

Comcast up 3.6% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

CMCSA

Comcast

$35.16

-1.05 (-2.90%)

07:11
01/23/19
01/23
07:11
01/23/19
07:11
Hot Stocks
Comcast raises annualized dividend by 10% to 84c per share »

Comcast announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

MTG

MGIC Investment

$11.63

-0.15 (-1.27%)

07:10
01/23/19
01/23
07:10
01/23/19
07:10
Hot Stocks
MGIC Investment announces executive promotions »

MGIC Investment's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Feb

UTX

United Technologies

$111.23

-2.7 (-2.37%)

07:10
01/23/19
01/23
07:10
01/23/19
07:10
Hot Stocks
United Technologies up over 4.5% after Q4 earnings beat, initial FY19 guidance »

United Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

CMCSA

Comcast

$35.16

-1.05 (-2.90%)

07:09
01/23/19
01/23
07:09
01/23/19
07:09
Hot Stocks
Comcast reports Q4 pro-forma revenue for Sky up 2.4% to $5B »

Pro Forma Revenue for Sky…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.